These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20830238)

  • 1. Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.
    Kirovski G; Gäbele E; Dorn C; Moleda L; Niessen C; Weiss TS; Wobser H; Schacherer D; Buechler C; Wasmuth HE; Hellerbrand C
    Int J Clin Exp Pathol; 2010 Aug; 3(7):675-80. PubMed ID: 20830238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation.
    Kirovski G; Dorn C; Huber H; Moleda L; Niessen C; Wobser H; Schacherer D; Buechler C; Wiest R; Hellerbrand C
    Exp Mol Pathol; 2011 Dec; 91(3):780-3. PubMed ID: 21855538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
    Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
    Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.
    Wouters K; van Gorp PJ; Bieghs V; Gijbels MJ; Duimel H; Lütjohann D; Kerksiek A; van Kruchten R; Maeda N; Staels B; van Bilsen M; Shiri-Sverdlov R; Hofker MH
    Hepatology; 2008 Aug; 48(2):474-86. PubMed ID: 18666236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation is independent of steatosis in a murine model of steatohepatitis.
    Wang W; Xu MJ; Cai Y; Zhou Z; Cao H; Mukhopadhyay P; Pacher P; Zheng S; Gonzalez FJ; Gao B
    Hepatology; 2017 Jul; 66(1):108-123. PubMed ID: 28220523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Pérez-Martínez L; Pérez-Matute P; Aguilera-Lizarraga J; Rubio-Mediavilla S; Narro J; Recio E; Ochoa-Callejero L; Oteo JA; Blanco JR
    J Antimicrob Chemother; 2014 Jul; 69(7):1903-10. PubMed ID: 24651825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase.
    Li ZZ; Berk M; McIntyre TM; Feldstein AE
    J Biol Chem; 2009 Feb; 284(9):5637-44. PubMed ID: 19119140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.
    Schnabl B; Czech B; Valletta D; Weiss TS; Kirovski G; Hellerbrand C
    Int J Clin Exp Pathol; 2011; 4(7):661-6. PubMed ID: 22076166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.
    Luo X; Li H; Ma L; Zhou J; Guo X; Woo SL; Pei Y; Knight LR; Deveau M; Chen Y; Qian X; Xiao X; Li Q; Chen X; Huo Y; McDaniel K; Francis H; Glaser S; Meng F; Alpini G; Wu C
    Gastroenterology; 2018 Dec; 155(6):1971-1984.e4. PubMed ID: 30213555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.
    Wortham M; He L; Gyamfi M; Copple BL; Wan YJ
    Dig Dis Sci; 2008 Oct; 53(10):2761-74. PubMed ID: 18299981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis.
    Kim BM; Abdelfattah AM; Vasan R; Fuchs BC; Choi MY
    Sci Rep; 2018 May; 8(1):7499. PubMed ID: 29760499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
    Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C
    Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary Mung Bean Protein Reduces Hepatic Steatosis, Fibrosis, and Inflammation in Male Mice with Diet-Induced, Nonalcoholic Fatty Liver Disease.
    Watanabe H; Inaba Y; Kimura K; Asahara SI; Kido Y; Matsumoto M; Motoyama T; Tachibana N; Kaneko S; Kohno M; Inoue H
    J Nutr; 2017 Jan; 147(1):52-60. PubMed ID: 27903831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.